In think you have to pay to attend. There is a link I'll share below.

Eversana was one of the main sponsors. Cameron is with some good company on the schedule, but I don't think it's regarding our information.

There is a brochure you can download with details, but I'm not sure how to share that.

https://momentumevents.com/fearlessinpharma/

Excellent adds and Good Luck !

LOL, Our day is coming!

Here is an article from 2018 covering the Car-T Landscape. A lot has changed since then with approvals but regardless it paints a picture of the growth and potential. Kerp in mind that 2020 was basically a scratched year with trials being difficult to conduct during Covid. So we have only had part of 2018, all of 2019 and parts of 2020 & 2021 with approved Car-T Therapies.

Lenzilumab if approved would become a prophylactic administered at time of Car-T to Prevent Cytokine Storm vs the current Standard of Care of treating the Cytokine Storm if it happens. The Phase I Trial of Lenzilumab in combination with Kite/Gilead's Yescarta although small showed that 1800 mg dosing performed perfectly (same dosing as Covid-19). Not only does Lenzilumab Prevent Cytokine Storm but it also enhances T Cells. So far Lenzilumab has been trialed in CD-19 CAR-T and the goal of opening a broad trial with Novartis Kymriah, Kite/Gilead Yescarta and Bristol Myers Breyanzi would also be focused on CD-19 CAR-T. I believe the companies goal is 150 Patient's with 50 Patients from each Company. Zuma-19 was originally planned for a Phase I Trial for dosing and then rolled into a Phase II with Kite/Gilead. There were 11 Hospital's enrolled for that trial which included Mayo Clinic, MD Anderson and Vanderbilt to name a few. I'm hopeful that these same Hospital's will be involved in the new proposed trial with all 3 major Car-T's .


https://medium.com/@nxpatel/next-generation-car-t-71b7159b2328

The company is testing Ifabotuzumab in solid Tumors, not sure how familiar you are with that one, but they just completed
a Phase I in Glioblastoma with positive results and are planning a Phase II trial.

This is an interesting study in Car-T Cytokine Storm following CD-19 CAR-T. The study was not based on Lenzilumab or Anti GM-CSF, but the reason I share it is it provides an outline of how CRS impacted a patient and was treated with JAK Inhibitor after treatment with curreny standard of care Tocilizumab failed.

There is no current prophylactic for Cytokine Release Syndrome and it is only treated after it's started. Lenzilumab is administered prophylacticly and not only prevents Cytokine Storm but it also enhances T-Cell Function.

Car-T is progressing rapidly and there are many different clinical trials underway. Lenzilumab's success in this area could have a huge impact on the evolution of Cancer Therapies.



https://journals.lww.com/md-journal/Fulltext/2021/05140/Using_JAK_inhibitor_to_treat_cytokine_release.33.aspx

Yeah Jay, that is shocking and sadly not suprising to me that they would have delayed inspections when we needed them most. I am very excited for European Agencies response to Lenzilumab as I think they have a better grasp on GM-CSF's role in Covid. We are sitting on a critical therapeutic regardless of vaccination rates, variants, etc. Listened to CNBC cover the Merck deal this morning, and it appears they also understand the story when it fits thier narrative, but just can't seem to find the Lenzilumab page in thier playbook. Once Healthcare gets access the smart Dr's will be able to take the wheel and get Lenz to those in need.

Great feedback Jay. I hadn't put much thought into, at least not to the level you have, and I'm happy to read your thoughts on Ken joining the $HGEN Team!

The longer they hold it down, the higher it will go as everyday passed $HGEN becomes even more derisked and further along in pipeline. I was happily buying shares in these ranges (pre-split) a year ago before NASDAQ, and at the beginning of a Phase III Trial and with so many unknowns. Anyone thinking that it's too late to start buying now, I'm here to tell you it's a great time to buy!

Great call today Jay! Was very happy to hear the NIH update and updated status regarding Foreign Government's as well. Of course my favorite part was Cameron talked about other areas outside of Covid.

Looking forward to today's $HGEN Fireside Chat

Details for the upcoming webcast is below:

Jefferies Healthcare Conference

Live Fireside Chat
Date: Wednesday, June 2, 2021
Time: 4:00 PM ET
Link: https://wsw.com/webcast/jeff174/hgen/1834542


https://ir.humanigen.com/news/news-details/2021/Humanigen-to-Present-at-Jefferies-Healthcare-Conference/default.aspx

Any idea on who who posting those 1,100's yesterday? Just curious if you remember

2100, 2100 let's go !

This great, thanks for sharing MWM! I have enjoyed watching your journey over this past year with $GME & $HGEN, the coverage is excellent!

Absolutely, been watching and holding. Very excited about Car-T and suggest everyone watch the video link posted yesterday by MWM from Cellicon 2021 hosted by Penn Medicine. The presentation talks about the Car-T landscape and is followed by a Presentation from Saad Kenderian where he covers Lenzilumab.


https://vimeopro.com/ajievents/celliconvalley21/video/543301659

What a great day in Lenzilumab Land! So much to unpack with all the news, and all very positive !

Excellent News! Everyday we progress another big step forward.

Nice Links, thanks fore sharing this

This a huge confirmation of what $HGEN is capable of and how that plays towards our future. I love it!

Yes, it's strange. I place to GTC Order and it's accepted and then a few days later when I go to check it will show as cancelled because it was to far away from current share price. Now I'm in the $240 range and it's held for last few days (just checked). Wonder if anybody else is having a similar issue? I should be able to set my GTC share price to whatever I want it to be. Don't think I had that issue in the past with other stocks and this only started with HGEN recently, maybe around the beginning of the year.

I started with sell orders in the $300's but TD keeps cancelling them saying they are to far away from current share price. I've been whittling the number down to the low $200's just so the order will stick incase lightning strikes while I'm busy being awesome somewhere that day.

The closing action of Friday reminded me very much of the days leading up to The PIPE Funding last year. It was hard to get orders filled, and the target kept moving. It could just be coincidence, but it felt different then most normal days around here. Low volume and moving targets. Looking forward to Monday.

Yes, and in some early analysts reporting they were only considering COVID and not including Car-T into thier estimates. Yesterday's Car-T news and relation to the Cytokine Storm caused in Covid was a huge confidence boost for Lenzilumab in Car-T.

Humanigen $HGEN received a Buy rating and $40 price target from Jefferies 4-star Analyst Kelly Shi (Jefferies) https://t.co/S9essI07Ko



https://www.tipranks.com/email-alert/96de0a9c-b43d-4811-a893-20beb82bffb7

How do you get that out of anything that was shared today?

LoL, that's hilarious! Might as well have some fun while we wait for the deals to be done.

Beautiful news today! Very happy to see the positive information regarding Car-T and even happier to hear that we will open up and include other Car-T's in Phase II.

Nice work MWM! Happy that you made that call, and what a surprise it will be for Jimmy to realize that the same guy that put him onto the whole $GME Shorts Fiasco is the same guy that called his show to point out $HGEN and Lenzilumab. The therapeutic that will be saving lives in Covid, and making this transition back to normalcy possible.

I love seeing more attention for Lenzilumab in Car-T. This seems to get completely overlooked with Covid, but Zuma-19 is on pace to provide Phase-I data in Q-2, and Phase II interim Data in Q-4. Currently active in 10 prestigious Hospitals.

Ha ha ha, what a way to power up your phone! Feeling very good about derisking, and the only thing standing the way is time. We've gotten pretty good at waiting, and the price games don't phase me. It's going to be a very good 2021 it seems.

Agreed, this was an important step and one hell of a day. Can't wait until we hit EUA, Ifab Data and Car-T Phase I, and NIH Data all during Q-2. Even bigger days are coming, ride the Bumps, hang on tight and smile as we go!


Good Luck Friend

Thank you for sharing this. I am very happy with results, and specifically the diversity of Patients enrolled. Looking forward to the progress in April.

WOW! Only the beginning here with Lenzilumab and Positive Data. Congratulations to all those that found HGEN and all those that soon will!

Good Luck CJames22, and nice work on the Reddit Post!

Happy to see that you are still following $HGEN even though you don't own any shares. Make sure you pay close attention this week so that you can see how it's done.

Vaccine EUA'S have been averaging 3 weeks from application to Approval. Not saying it will be this quick for Lenzilumab, but it's nice to have something to compare to.




https://stocktwits.com/Knuckle_Sandwich/message/309307919

Very nice, thank you for sharing this

That's the spirit, happy that you found us.

Q-2 should be a lot of fun for $HGEN

1. We will have Phase III and hopefully waiting on EUA

2. April 10th at AACR we get our first glimpse into Ifabotuzumab in Glioblastoma & Solid Tumors

3. We see Phase I Car-t Zuma-19 Data with Kite/Gilead

4. NIH ACTIV-5 Topline Data


https://ir.humanigen.com/events-and-presentations/default.aspx

Absolutely! Nothing has changed, except that the time to data release is closer today then it was yesterday. I have firmed up my decisions to Buy & Hold over the last year with new information as it has become available. The latest GM-CSF Paper's really cemented $HGEN and Lenzilumab for me.